CA2328431C - Plasmin inhibitors from the australian brown snake pseudonaja textilis textilis - Google Patents

Plasmin inhibitors from the australian brown snake pseudonaja textilis textilis Download PDF

Info

Publication number
CA2328431C
CA2328431C CA2328431A CA2328431A CA2328431C CA 2328431 C CA2328431 C CA 2328431C CA 2328431 A CA2328431 A CA 2328431A CA 2328431 A CA2328431 A CA 2328431A CA 2328431 C CA2328431 C CA 2328431C
Authority
CA
Canada
Prior art keywords
preparation
plasmin
plasmin inhibitor
glu
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2328431A
Other languages
English (en)
French (fr)
Other versions
CA2328431A1 (en
Inventor
Pantaleone Paul Masci
Martin Francis Lavin
Patrick Joseph Gaffney
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Venomics Pty Ltd
Original Assignee
University of Queensland UQ
National Institute for Biological Standards and Control
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Queensland UQ, National Institute for Biological Standards and Control filed Critical University of Queensland UQ
Publication of CA2328431A1 publication Critical patent/CA2328431A1/en
Application granted granted Critical
Publication of CA2328431C publication Critical patent/CA2328431C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2328431A 1998-05-11 1999-05-07 Plasmin inhibitors from the australian brown snake pseudonaja textilis textilis Expired - Fee Related CA2328431C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPP3450A AUPP345098A0 (en) 1998-05-11 1998-05-11 Novel anti-fibrinolytic agents
AUPP3450 1998-05-11
PCT/AU1999/000343 WO1999058569A1 (en) 1998-05-11 1999-05-07 PLASMIN INHIBITORS FROM THE AUSTRALIAN BROWN SNAKE $i(PSEUDONAJA TEXTILIS TEXTILIS)

Publications (2)

Publication Number Publication Date
CA2328431A1 CA2328431A1 (en) 1999-11-18
CA2328431C true CA2328431C (en) 2010-04-27

Family

ID=3807704

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2328431A Expired - Fee Related CA2328431C (en) 1998-05-11 1999-05-07 Plasmin inhibitors from the australian brown snake pseudonaja textilis textilis

Country Status (11)

Country Link
US (1) US7070969B1 (https=)
EP (1) EP1078003B1 (https=)
JP (1) JP4542705B2 (https=)
AT (1) ATE440108T1 (https=)
AU (1) AUPP345098A0 (https=)
CA (1) CA2328431C (https=)
DE (1) DE69941292D1 (https=)
DK (1) DK1078003T3 (https=)
ES (1) ES2332249T3 (https=)
NZ (1) NZ508770A (https=)
WO (1) WO1999058569A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP345098A0 (en) * 1998-05-11 1998-06-04 National Institute Of Biological Standards And Control, United Kingdom Novel anti-fibrinolytic agents
US6506365B1 (en) * 2000-09-25 2003-01-14 Baxter Aktiengesellschaft Fibrin/fibrinogen binding conjugate
US7745192B2 (en) 2002-04-03 2010-06-29 Venomics Pty Limited Prothrombin activating protein
ES2431526T3 (es) 2005-12-29 2013-11-26 The Regents Of The University Of California Office Of Technology Transfer Procedimientos y composiciones relacionadas con el dominio Kunitz I mutante de TFPI-2
EP2154152A1 (en) * 2008-08-08 2010-02-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Use of Conkunitzin-S1 for the modulation of glucose-induced insulin secretion
US20110287036A1 (en) * 2008-11-17 2011-11-24 Riken Novel cancer targeting therapy using complex of subtance capable of binding specifically to constituent factor of cancer stroma and anti-tumor compound
CN102850451B (zh) * 2011-06-29 2014-05-07 辽宁诺康生物制药有限责任公司 具有抑制纤溶酶活性的重组textilinin-1及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342830A (en) * 1990-11-16 1994-08-30 Cor Therapeutics, Inc. Antithrombosis agents
EP0585504A1 (en) * 1992-09-04 1994-03-09 Pentapharm A.G. Phospholipid dependant prothrombin activator and its use in lupus anticoagulant testing
AUPP076797A0 (en) * 1997-12-05 1998-01-08 Active (Pla) R&D Pty Ltd Phospholipase inhibitor
AUPP345098A0 (en) * 1998-05-11 1998-06-04 National Institute Of Biological Standards And Control, United Kingdom Novel anti-fibrinolytic agents

Also Published As

Publication number Publication date
ATE440108T1 (de) 2009-09-15
CA2328431A1 (en) 1999-11-18
DE69941292D1 (de) 2009-10-01
NZ508770A (en) 2003-12-19
EP1078003B1 (en) 2009-08-19
AUPP345098A0 (en) 1998-06-04
ES2332249T3 (es) 2010-01-29
EP1078003A1 (en) 2001-02-28
JP4542705B2 (ja) 2010-09-15
WO1999058569A1 (en) 1999-11-18
JP2002514404A (ja) 2002-05-21
US7070969B1 (en) 2006-07-04
DK1078003T3 (da) 2009-12-07
EP1078003A4 (en) 2004-08-25

Similar Documents

Publication Publication Date Title
KR100278036B1 (ko) 사람 쿠니즈형 프로테아제 저해제 변이체
Bock et al. Cloning and expression of the cDNA for human antithrom, bin III
CA1336493C (en) Pharmaceutically active combination of plasminogen activator and thrombin inhibitor
JP3122127B2 (ja) 抗凝血タンパク質
JP2655752B2 (ja) 組換えヒト第▲ｖｉｉｉ▼因子誘導体
AU643306B2 (en) Anticoagulant polypeptides
AU671611B2 (en) Human kunitz-type protease inhibitor variants
KR19980703173A (ko) 히루딘의 아미노산 서열에 기초한 트롬빈 억제제
ZA200101861B (en) Factor Vlla inhibitors.
CZ164494A3 (en) Human variant of kunitz-type protease inhibitor
JPWO1992000325A1 (ja) 抗血液凝固活性を有するポリペプチド
US5239058A (en) Proteins having anticoagulant properties
CA2328431C (en) Plasmin inhibitors from the australian brown snake pseudonaja textilis textilis
IE903245A1 (en) Proteins having anticoagulant activity
Filippovich et al. A family of textilinin genes, two of which encode proteins with antihaemorrhagic properties
WO1998004717A2 (en) Double-stranded rna dependent protein kinase derived peptides to promote proliferation of cells and tissues in a controlled manner
KR20130099027A (ko) 혈전용해 및 응고억제 특성을 갖는 단백질 융합 구조물
AU759190B2 (en) Plasmin inhibitors from the Australian brown snake (Pseudonaja textilis textilis)
JPH05339292A (ja) ヒトアンチトロンビンｉｉｉ変異体
FI110669B (fi) Menetelmiä luonnosta eristettävissä tai synteettisesti valmistettavissa olevien trombiini-inhibiittorien valmistamiseksi
US5443827A (en) Fibrin-targeted inhibitors of thrombin
KR20060133031A (ko) 트롬빈 유도체 및 그것을 포함하는 의약 조성물
US5328997A (en) Processes for making proteins having anticoagulant properties
JPH1080281A (ja) 新規蛋白質及びその製造方法
WO1992018139A1 (en) Chimeric molecule with plasminogen activator activity and affinity for atherosclerotic plaques

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20130507